NCT04793620View on ClinicalTrials.gov

Pertussis Acellular Vaccine Adjuvanted With TQL1055

PHASE1TerminatedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

August 23, 2021

Study Completion Date

February 14, 2022

Conditions
Pertussis
Interventions
OTHER

TQL1055

Semisynthetic saponin adjuvant

BIOLOGICAL

Acellular pertussis vaccine

Acellular pertussis vaccine

Trial Locations (1)

Unknown

Q-Pharm, Brisbane

Sponsors
All Listed Sponsors
lead

Adjuvance Technologies, Inc.

INDUSTRY

NCT04793620 - Pertussis Acellular Vaccine Adjuvanted With TQL1055 | Biotech Hunter | Biotech Hunter